Freising, July 26, 2017 /XL-protein/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a license agreement with XL-protein GmbH (“XLp”) for the rights to develop, manufacture and commercialize products using XLp’s PASylation® Technology to extend the plasma half-life of selected asparaginase product candidates. Under the terms of the agreement, Jazz […]
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png00web28627236https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.pngweb286272362017-07-26 23:11:392017-07-27 14:13:10Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates
Melbourne, Australia and FREISING, Germany, 7 November 2016: AdAlta Ltd (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, and XL-protein GmbH, a privately owned German biopharmaceutical company specialized in the design of biobetters with extended half-life, announced today that they have entered into a collaboration on the development and commercialization […]
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png00web28627236https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.pngweb286272362016-11-07 09:40:132017-07-26 23:15:50AdAlta and XL-protein announce collaboration to develop a long acting version of its lead fibrosis drug candidate AD-114 using PASylation® Technology
NEW YORK, LONDON, and FREISING, Germany, April 14, 2016 – Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, and XL-protein, a privately owned biopharmaceutical company, announced today that they have entered into a License, Development and Commercialization Agreement. This partnership is focused on developing a second generation, longer acting version of Coversin. Under […]
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png00web28627236https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.pngweb286272362016-06-14 07:15:462016-09-27 09:17:51Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology
Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates
/in News /by web28627236Freising, July 26, 2017 /XL-protein/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a license agreement with XL-protein GmbH (“XLp”) for the rights to develop, manufacture and commercialize products using XLp’s PASylation® Technology to extend the plasma half-life of selected asparaginase product candidates. Under the terms of the agreement, Jazz […]
AdAlta and XL-protein announce collaboration to develop a long acting version of its lead fibrosis drug candidate AD-114 using PASylation® Technology
/in News /by web28627236Melbourne, Australia and FREISING, Germany, 7 November 2016: AdAlta Ltd (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, and XL-protein GmbH, a privately owned German biopharmaceutical company specialized in the design of biobetters with extended half-life, announced today that they have entered into a collaboration on the development and commercialization […]
Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology
/in News /by web28627236NEW YORK, LONDON, and FREISING, Germany, April 14, 2016 – Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, and XL-protein, a privately owned biopharmaceutical company, announced today that they have entered into a License, Development and Commercialization Agreement. This partnership is focused on developing a second generation, longer acting version of Coversin. Under […]